$KRTL KRTL Biotech Highlights Ophthalmic Pharmaceu
Post# of 99736
(Total Views: 107)
Posted On: 11/21/2025 10:23:25 AM
$KRTL KRTL Biotech Highlights Ophthalmic Pharmaceutical Capabilities to Address Vision Care Needs in Emerging and Global Markets
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=501153
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company"
today announced a new category spotlight on ophthalmology, emphasizing its plans to support access to essential eye care treatments through its subsidiary, KRTL Biotech Inc., and Bolivian manufacturing partner, Industria Químico-Farmacéutica SIGMA Corp. S.R.L. ("SIGMA" .
The ophthalmic pharmaceutical market continues to expand globally, with increasing demand for solutions to treat infections, allergies, inflammation, and chronic conditions such as dry eye and glaucoma. Access to affordable and reliable ophthalmic products is particularly important in underserved health systems and rural populations where vision care options are limited.
KRTL Biotech, through its strategic partnership with SIGMA, is actively evaluating and preparing formulations aligned with these needs, including antibiotic eye drops, antihistamines, and preservative-free ocular solutions. SIGMA’s GMP-compliant manufacturing facility supports aseptic production processes and sterile packaging suitable for ophthalmic dosage forms. Products currently sold in Bolivia include Gentamicol, a broad-spectrum antibiotic eye drop; Lubricol, an ocular lubricant; and Glaucol-T, formulated to help manage intraocular pressure.
"Vision health is often overlooked, but it is a fundamental part of public health," said Patricia Wilstermann, CEO of SIGMA Corp. "We are proud that our platform has the capacity and quality systems to support the development and export of safe, effective ophthalmic medicines to meet growing regional and international demand."
Ophthalmic products will form part of KRTL Biotech’s broader portfolio strategy to deliver high-need, high-compliance treatments into the U.S. and LATAM markets. The Company is currently researching regulatory pathways for select formulations under the U.S. FDA's Over-the-Counter (OTC) monograph system and Abbreviated New Drug Application (ANDA) processes, as well as exploring opportunities in institutional procurement channels.
"Our pharmaceutical expansion is guided by medical relevance and regulatory scalability," said Cesar Herrera, CEO of KRTL Holding Group Inc. "Ophthalmology represents a strong growth area, and with SIGMA’s validated production environment, we are well-positioned to deliver products that align with both clinical value and access objectives."
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=501153
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company"
today announced a new category spotlight on ophthalmology, emphasizing its plans to support access to essential eye care treatments through its subsidiary, KRTL Biotech Inc., and Bolivian manufacturing partner, Industria Químico-Farmacéutica SIGMA Corp. S.R.L. ("SIGMA" . The ophthalmic pharmaceutical market continues to expand globally, with increasing demand for solutions to treat infections, allergies, inflammation, and chronic conditions such as dry eye and glaucoma. Access to affordable and reliable ophthalmic products is particularly important in underserved health systems and rural populations where vision care options are limited.
KRTL Biotech, through its strategic partnership with SIGMA, is actively evaluating and preparing formulations aligned with these needs, including antibiotic eye drops, antihistamines, and preservative-free ocular solutions. SIGMA’s GMP-compliant manufacturing facility supports aseptic production processes and sterile packaging suitable for ophthalmic dosage forms. Products currently sold in Bolivia include Gentamicol, a broad-spectrum antibiotic eye drop; Lubricol, an ocular lubricant; and Glaucol-T, formulated to help manage intraocular pressure.
"Vision health is often overlooked, but it is a fundamental part of public health," said Patricia Wilstermann, CEO of SIGMA Corp. "We are proud that our platform has the capacity and quality systems to support the development and export of safe, effective ophthalmic medicines to meet growing regional and international demand."
Ophthalmic products will form part of KRTL Biotech’s broader portfolio strategy to deliver high-need, high-compliance treatments into the U.S. and LATAM markets. The Company is currently researching regulatory pathways for select formulations under the U.S. FDA's Over-the-Counter (OTC) monograph system and Abbreviated New Drug Application (ANDA) processes, as well as exploring opportunities in institutional procurement channels.
"Our pharmaceutical expansion is guided by medical relevance and regulatory scalability," said Cesar Herrera, CEO of KRTL Holding Group Inc. "Ophthalmology represents a strong growth area, and with SIGMA’s validated production environment, we are well-positioned to deliver products that align with both clinical value and access objectives."
(0)
(0)